Executive Profiles

Insights from AmerisourceBergen EVP and Chief Strategy Officer, Leslie Donato.

GSK‘s President of US Pharmaceuticals, Maya Martinez-Davis, outlines her organization’s evolving diversity and inclusion commitments.

Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.

Newly appointed General Manager (UK) at Global Blood Therapeutics (GBT), Nigel Nicholls talks about the company’s vision for Europe and the UK and the health inequity faced by the sickle cell disease community.

Harvard Business School Professor Joseph B. Fuller talks about the future prospects for pharma sales forces as they face more restrictions on accessing their target physicians and looming concerns of automation.

Alnylam's new Chief Commercial Officer, Tolga Tanguler, talks about his new role and what he envisions for the company in the next five years.

Building on a lifelong passion for biomedical research, and then its application in policy and health equity as a leader in various interconnected settings, Michelle McMurry-Heath, president and CEO of BIO, is uniquely positioned as a “translator” for science and social advocacy—and speaking stakeholders to action.

Amgen board member and serial CEO Fred Hassan talks about the three levers Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.

Annovis Bio's Maria L. Maccecchini, Ph.D., talks about why she, as a scientist and biotech company entrepreneur, became focused on protecting nerve cells in the brain and in the body, as a way to treat neurodegenerative disease.

David Johnson, Global Director Commercial Excellence at ADVANZ PHARMA, talks about the importance of ensuring the continued supply of complex medicines to European hospitals, to enhance access to critical medicines, helping to broaden patient choice and optimize health outcomes.

Early career ‘assist’ ignites calling in data and healthcare disruption.

Learning from others and leading by example provides full-circle success.

Going all-in on accelerating the promise of cell therapy at larger scale.

Script change from destined life in research to wild pace of biotech pays off.

From big pharma to underdog biotech, a mission to empower.

Applying a love for numbers in tackling drug-access delays around the world.

Bridging science and business with the end user in mind.

Excelling in specialty launch while paying it forward.

A passion for building the business engine behind treatments for rare disease.

Throwback scientist and entrepreneur leads quest to maximize gains in population health.

Startup CEO touts immunology technology to cure cancer and more.

Launching a big pharma biotech incubator during the pandemic.

Academic-focused leader advocates questioning and communicating to advance science.

Mike Gladstone, Pfizer’s Global President of Inflammation & Immunology (I&I), talks about how the company is addressing the unmet need in I&I and how its relationships with patients is fueling the quest for breakthroughs over ‘me too’ incremental improvements

Pascal Descargues, Ph.D., founder of Genoskin, talks about how the company is responding to the US government’s push to help pharma and biotech leaders speed clinical drug development and testing.